DK167209B1 - Synergistisk aktivt praeparat til behandling af hypertension - Google Patents

Synergistisk aktivt praeparat til behandling af hypertension Download PDF

Info

Publication number: DK167209B1
Authority: DK; Denmark
Prior art keywords: prazosin; cyclic amp; piroximone; synergistic; amrinone
Prior art date: 1986-11-05

Application number

DK578887A

Other languages

Danish (da)

English (en)

Other versions

DK578887D0 (da

DK578887A (da

Inventor

Richard C Dage

Original Assignee

Merrell Dow Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-05

Filing date

1987-11-04

Publication date

1993-09-20

1987-11-04 Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma

1987-11-04 Publication of DK578887D0 publication Critical patent/DK578887D0/da

1988-05-06 Publication of DK578887A publication Critical patent/DK578887A/da

1993-09-20 Application granted granted Critical

1993-09-20 Publication of DK167209B1 publication Critical patent/DK167209B1/da

Links

206010020772 Hypertension Diseases 0.000 title claims description 4
230000002195 synergetic effect Effects 0.000 title abstract description 16
239000000496 cardiotonic agent Substances 0.000 claims abstract description 13
229960001289 prazosin Drugs 0.000 claims description 23
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 23
OQGWJZOWLHWFME-UHFFFAOYSA-N 4-ethyl-5-(pyridine-4-carbonyl)-1,3-dihydroimidazol-2-one Chemical compound N1C(=O)NC(C(=O)C=2C=CN=CC=2)=C1CC OQGWJZOWLHWFME-UHFFFAOYSA-N 0.000 claims description 11
229950010078 piroximone Drugs 0.000 claims description 11
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 10
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 10
229940095074 cyclic amp Drugs 0.000 claims description 10
229960002105 amrinone Drugs 0.000 claims description 9
RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 claims description 9
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 8
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 claims description 8
230000000747 cardiac effect Effects 0.000 claims description 8
230000002401 inhibitory effect Effects 0.000 claims description 6
239000002160 alpha blocker Substances 0.000 claims description 5
230000002708 enhancing effect Effects 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
230000009471 action Effects 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
230000004531 blood pressure lowering effect Effects 0.000 abstract description 3
239000002220 antihypertensive agent Substances 0.000 abstract description 2
125000004122 cyclic group Chemical group 0.000 abstract description 2
108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 abstract 1
102000015009 alpha1-adrenergic receptor activity proteins Human genes 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
229940030600 antihypertensive agent Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
230000036772 blood pressure Effects 0.000 description 7
230000003276 anti-hypertensive effect Effects 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 5
238000011699 spontaneously hypertensive rat Methods 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000037396 body weight Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
230000010339 dilation Effects 0.000 description 1
230000004217 heart function Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000001057 ionotropic effect Effects 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
229960005414 pirbuterol Drugs 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000012876 topography Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK578887A 1986-11-05 1987-11-04 Synergistisk aktivt praeparat til behandling af hypertension DK167209B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92778586A	1986-11-05	1986-11-05
US92778586		1986-11-05

Publications (3)

Publication Number	Publication Date
DK578887D0 DK578887D0 (da)	1987-11-04
DK578887A DK578887A (da)	1988-05-06
DK167209B1 true DK167209B1 (da)	1993-09-20

Family

ID=25455252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK578887A DK167209B1 (da)	1986-11-05	1987-11-04	Synergistisk aktivt praeparat til behandling af hypertension

Country Status (11)

Country	Link
EP (1)	EP0268146B1 (de)
JP (1)	JP2612175B2 (de)
KR (1)	KR950013758B1 (de)
AT (1)	ATE59781T1 (de)
DE (1)	DE3767287D1 (de)
DK (1)	DK167209B1 (de)
ES (1)	ES2036560T3 (de)
GR (1)	GR3001375T3 (de)
IE (1)	IE59905B1 (de)
PH (1)	PH23818A (de)
ZA (1)	ZA878182B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU749703B2 (en) *	1997-05-19	2002-07-04	Repros Therapeutics Inc.	Combination therapy for modulating the human sexual response
ES2258300T3 (es) *	1997-12-16	2006-08-16	Pfizer Products Inc.	Combinacion de antagonistas del receptor alfa-1-adrenergico y un inhibidor gmpc pdev para el tratamiento de la impotencia.
DE102004011512B4 (de)	2004-03-08	2022-01-13	Boehringer Ingelheim Vetmedica Gmbh	Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (de)	2004-03-25	2005-09-28	Boehringer Ingelheim Vetmedica Gmbh	Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern
US8980894B2 (en)	2004-03-25	2015-03-17	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (de)	2006-11-07	2008-05-14	Boehringer Ingelheim Vetmedica Gmbh	Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat
EP3167876B1 (de)	2012-03-15	2021-09-08	Boehringer Ingelheim Vetmedica GmbH	Pharmazeutische tablettenformulierung für den veterinärmedizinischen sektor, verfahren zur herstellung und verwendung davon
US20130274245A1 (en) *	2012-04-11	2013-10-17	Jan BLUMENSTEIN	Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia
EP3021832B9 (de)	2013-07-19	2023-03-15	Boehringer Ingelheim Vetmedica GmbH	Konservierte veretherte cyclodextrinderivate mit flüssiger, wässriger pharmazeutischer zusammensetzung
CA2930033C (en)	2013-12-04	2022-12-13	Boehringer Ingelheim Vetmedica Gmbh	Improved pharmaceutical compositions of pimobendan
US10537570B2 (en)	2016-04-06	2020-01-21	Boehringer Ingelheim Vetmedica Gmbh	Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4130647A (en) *	1977-07-08	1978-12-19	Pfizer Inc.	Methods for treating congestive heart failure and ischemic heart disease
US4601897A (en) *	1985-11-06	1986-07-22	Pfizer Inc.	Prazosin-pirbuterol combination for bronchodilation

1987
- 1987-10-30 ZA ZA878182A patent/ZA878182B/xx unknown
- 1987-11-04 PH PH36022A patent/PH23818A/en unknown
- 1987-11-04 AT AT87116236T patent/ATE59781T1/de not_active IP Right Cessation
- 1987-11-04 ES ES198787116236T patent/ES2036560T3/es not_active Expired - Lifetime
- 1987-11-04 EP EP87116236A patent/EP0268146B1/de not_active Expired - Lifetime
- 1987-11-04 DK DK578887A patent/DK167209B1/da not_active IP Right Cessation
- 1987-11-04 IE IE297587A patent/IE59905B1/en not_active IP Right Cessation
- 1987-11-04 DE DE8787116236T patent/DE3767287D1/de not_active Expired - Lifetime
- 1987-11-04 KR KR1019870012354A patent/KR950013758B1/ko not_active Expired - Lifetime
- 1987-11-05 JP JP62278440A patent/JP2612175B2/ja not_active Expired - Lifetime
1991
- 1991-01-24 GR GR91400079T patent/GR3001375T3/el unknown

Also Published As

Publication number	Publication date
IE872975L (en)	1988-05-05
PH23818A (en)	1989-11-23
GR3001375T3 (en)	1992-09-11
KR950013758B1 (ko)	1995-11-15
KR880005934A (ko)	1988-07-21
JPS63132837A (ja)	1988-06-04
JP2612175B2 (ja)	1997-05-21
DE3767287D1 (de)	1991-02-14
ES2036560T3 (es)	1993-06-01
ATE59781T1 (de)	1991-01-15
DK578887D0 (da)	1987-11-04
ZA878182B (en)	1988-05-02
EP0268146B1 (de)	1991-01-09
IE59905B1 (en)	1994-04-20
EP0268146A1 (de)	1988-05-25
DK578887A (da)	1988-05-06

Legal Events

Date	Code	Title	Description
1993-09-20	B1	Patent granted (law 1993)
2007-11-19	PUP	Patent expired

Publication	Publication Date	Title
DK167209B1 (da)	1993-09-20	Synergistisk aktivt praeparat til behandling af hypertension
BRPI0513565A (pt)	2008-05-06	composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
DE60315674D1 (de)	2007-09-27	Neue imidazopyridine und ihre verwendung
JP2005502643A5 (de)	2006-01-05
KR20040078127A (ko)	2004-09-08	발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
RU2003114752A (ru)	2004-09-10	Лечение желудочно-кишечных стромальных опухолей
JP2007506752A (ja)	2007-03-22	肺動脈高血圧症を治療するための併用療法におけるイロプロスト
KR20010023331A (ko)	2001-03-26	혈관신생 촉진제 및 혈관신생 작용증강제
DE60305514D1 (de)	2006-06-29	Neue verwendung von benzothiazolderivaten
JPS6197228A (ja)	1986-05-15	ジヒドロピリジン類とａｃｅ阻害剤との配合物
ATE324890T1 (de)	2006-06-15	Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
MX2021013942A (es)	2022-01-04	Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
US4868182A (en)	1989-09-19	Enhancement of prazosin
TW201006823A (en)	2010-02-16	Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
JP2017014224A (ja)	2017-01-19	帯状疱疹関連痛の急性期疼痛の予防又は治療剤
TW201026684A (en)	2010-07-16	Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy
ES2215990T3 (es)	2004-10-16	Antagonistas del receptor 5-ht2 para tratar enfermedades venosas.
JPS63141934A (ja)	1988-06-14	ディルチアゼムおよびアンギオテンシン変換酵素阻害剤を含有する医薬組成物
JP2005501825A5 (de)	2006-01-05
JP4942297B2 (ja)	2012-05-30	肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用
JP2006505582A5 (de)	2006-12-07
RU2009149637A (ru)	2011-07-20	Композиции, применимые для лечения гастроэзофагеальной рефлюксной болезни
JPH107570A (ja)	1998-01-13	パーキンソン病予防・治療剤
JPWO2010131460A1 (ja)	2012-11-01	テガフール・ギメラシル・オテラシルカリウム配合剤及びオキサリプラチンを含有する抗腫瘍剤
EP2033646A1 (de)	2009-03-11	Vorbeugender und/oder therapeutischer wirkstoff für rheumatoide arthritis